 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 CDK7 inhibitor, demonstrating clinical activity at tolerable doses as a single agent across multiple tumor types. The data is being presented today in an oral presentation at the 2021 